2002 Results
Sort By:
Published on July 21, 2017
Boehringer Ingelheim will apply Philogen’s proprietary Encoded Self-Assembling Chemical (ESAC) library technology platform to discover and optimize novel small-molecule–based therapeutics, through a collaboration whose value was not disclosed. ESAC enables Philogen to construct and screen DNA-encoded chemical libraries that according to the company are of unprecedented size and quality. Philogen…
Published on July 12, 2017
The FDA is vowing to expand its commitment to precision medicine, citing two recent biomarker-based approvals of new indications for marketed drugs, as well as recent progress in developing master protocols, case studies, and biomarker qualification standards. In a post on FDA’s blog, Janet Woodcock, M.D., director of the agency’s…
Published on July 3, 2017
Despite the signficant promise of CRISPR to correct the genetic underpinnings of disease, the technology still has signficant risk off-target effects—instances when non-targeted genes are altered. Scientists from The University of Texas at Austin took an important step toward safer gene-editing cures for life-threatening disorders, from cancer to HIV to…
Published on June 30, 2017
Illumina has won FDA approval for its Extended RAS Panel, a next-generation sequencing (NGS) kit for use with the company’s MiSeqDx System to help clinicians identify patients eligible for treatment of metastatic colorectal cancer (mCRC) with Amgen’s marketed drug Vectibix® (panitumumab). “Together with Amgen, we've developed a companion diagnostic test…
Published on June 28, 2017
New research published in Proceedings of the National Academy of Sciences shows that DNA methylation can provide effective markers for predicting the prognosis and survival of four cancers. “We report that methylation patterns can predict the prognosis and survival, with good correlation between differential methylation of CpG sites and expression…
Published on June 26, 2017
Biodata gold is all around us, but it is hard to find, distributed as it is in traces throughout a vast biodata landscape, one that has scarcely been explored properly, even as it continues to be reshaped by next-generation sequencing, the effects of which are, well, tectonic. Thus far, biodata…
Published on June 23, 2017
The largest genetic sequencing study of osteosarcoma to date has revealed that some patients with osteosarcoma could be helped by existing treatments. A team of researchers from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopedic Hospital NHS Trust, has found that 10% of…
Published on June 23, 2017
In what Thermo Fisher Scientific officials are calling an “historic, path-breaking event,” the FDA has granted premarket approval to the company’s Oncomine Dx Target Test, which screens tumor samples for biomarkers associated with three FDA-approved drugs for non-small cell lung cancer (NSCLC). The panel-based test evaluates 23 different biomarkers simultaneously and…
Published on June 21, 2017
Adaptive Biotechnologies said today it will partner with Johnson & Johnson’s Janssen Biotech to develop its next-generation sequencing (NGS)-based clonoSEQ Assay as a companion diagnostic in ongoing and future clinical trials assessing Darzalex (daratumumab) in patients with multiple myeloma (MM). The value of the collaboration was not disclosed. The companies…
Published on June 21, 2017
New research led by a group of investigators from Emory University builds toward the hope of using CRISPR/Cas9 gene editing to alleviate the genetic roots of disease. In research published in the Journal of Clinical Investigation, researchers showed how the CRISPR/Cas9 system could delete part of a gene that produces toxic…
Published on June 16, 2017
Agilent Technologies said today it has won expanded use for its Dako PD-L1 IHC 28-8 pharmDx test in Europe for an additional oncology indication, urothelial cancer, in patients who are most likely to benefit from treatment with the Bristol-Myers Squibb (BMS) marketed cancer immunotherapy Opdivo (nivolumab). PD-L1 IHC 28-8 pharmDx…
Published on June 14, 2017
Personal Genome Diagnostics said today it won a contract from the U.S. Department of Veterans Affairs (VA) to provide its PlasmaSELECT™ 64 liquid biopsy profiling assay to advanced cancer patients being treated at VA facilities. The value of the contract was not disclosed. PlasmaSELECT will be the first plasma-based genomic profiling…
Published on June 9, 2017
Foundation Medicine and Caris Life Sciences will alert physicians to patients who are eligible for the National Cancer Institute’s Phase II NCI-MATCH (Molecular Analysis for Therapy Choice) study, through separate collaborations announced this week. The companies said they will inform the physicians, who will work from more than 1,100 clinical…
Published on June 7, 2017
London-based medical research charity MRC Technology (MRCT) and Belgian molecular diagnostic developer Biocartis Group announced a partnership that will see the two entities work to develop a range of diagnostic tests on the Biocartis Idylla platform. The first project will be a new liquid biopsy test for the monitoring of…
Published on June 7, 2017
Delivering precision medicine to late-stage cancer patients is the goal of a “turnkey” informatics solution that integrates offerings from both Royal Philips and Navican, a wholly-owned spinout of Intermountain Healthcare. The solution will apply Navican's TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics cloud-based precision medicine platform, which integrates…